# HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease

> **NCT05813860** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 976 (estimated)

## Conditions studied

- Crohn Disease
- Infliximab

## Interventions

- **DRUG:** Azathioprine
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT05813860
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-04-30
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 976 (ESTIMATED)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05813860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05813860, "HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05813860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*